Abstract:Background & aimsThe effectiveness of adjuvant immunotherapy to diminish recurrence and improve long-term prognosis following curative-intent surgical resection for hepatocellular carcinoma (HCC) is of increased interest, especially among individuals at high risk of recurrence. The objective of the current study was to investigate the impact of adjuvant immunotherapy on long-term recurrence and survival after curative resection among patients with intermediate/advanced HCC.MethodsUsing a prospectively-collected multicenter database, patients who underwent curative-intent resection for Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC were identified. Propensity score matching (PSM) analysis was used to compare recurrence-free survival (RFS) and overall survival (OS) between patients treated with and without adjuvant immune checkpoint inhibitors (ICIs). Multivariate Cox-regression analysis further identified independent factors of RFS and OS.ResultsAmong the 627 enrolled patients, 109 patients (23.3%) received adjuvant immunotherapy. Most ICI-related adverse reactions were grading I-II. PSM analysis created 99 matched pairs of patients with comparable baseline characteristics between patients treated with and without adjuvant immunotherapy. In the PSM cohort, the median RFS (29.6 vs. 19.3 months, P=0.031) and OS (35.1 vs. 27.8 months, P=0.036) were better among patients who received adjuvant immunotherapy versus patients who did not. After adjustment for other confounding factors on multivariable analyzes, adjuvant immunotherapy remained independently associated with favorable RFS (HR: 0.630; 95% CI: 0.435-0.914; P=0.015) and OS (HR: 0.601; 95% CI: 0.401-0.898; P=0.013). Subgroup analyzes identified potentially prognostic benefits of adjuvant immunotherapy among patients with intermediate-stage and advanced-stage HCC.ConclusionThis real-world observational study demonstrated that adjuvant immunotherapy was associated with improved RFS and OS following curative-intent resection of intermediate/advanced HCC. Future randomized controlled trials are warranted to establish definitive evidence for this specific population at high risks of recurrence.

The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients

Cytokine-Induced Killer (cik) Cell Therapy for Patients with Hepatocellular Carcinoma: Efficacy and Safety

Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma.

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma after Curative Resection

Autologous Transplantation of Cytokine-Induced Killer Cells As an Adjuvant Therapy for Hepatocellular Carcinoma in Asia: an Update Meta-Analysis and Systematic Review.

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.

Adjuvant Cytokine-Induced Killer Cells with Minimally Invasive Therapies Augmented Therapeutic Efficacy of Unresectable Hepatocellular Carcinoma

A Randomized Controlled Trial on Patients with or Without Adjuvant Autologous Cytokine-Induced Killer Cells after Curative Resection for Hepatocellular Carcinoma.

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.

A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma.

Minimally Invasive Treatment Combined With Cytokine-Induced Killer Cells Therapy Lower The Short-Term Recurrence Rates Of Hepatocellular Carcinomas

A Meta-Analysis of Cytokine-Induced Killer Cells Therapy in Combination with Minimally Invasive Treatment for Hepatocellular Carcinoma.

Adjuvant Immunotherapy Improves Recurrence-Free and Overall Survival Following Surgical Resection for Intermediate/advanced Hepatocellular Carcinoma a Multicenter Propensity Matching Analysis

[Cytokine-Induced Killer Cells Transfusion Following Minimally Invasive and Interventional Therapy for Early-Stage Hepatocellular Carcinoma:A Long-Term Study].

Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma]

High number of PD‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients

High number of PD-1 positive intratumoral lymphocytes predict survival benefit of CIK cells for hepatocellular carcinoma patients.

[Cytokine-Induced Killer Cell Fusion to Lower Recurrence of Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization Sequentially Combined with Radiofrequency Ablation: a Randomized Trial].

Adoptive Immunotherapy For Postoperative Hepatocellular Carcinoma: A Systematic Review